MAM
ABUS icon

Martingale Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Martingale Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$927K Buy
+193,100
New +$848K 0.02% 552

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Martingale Asset Management's ABUS Position: Q2 2026 in Review

Martingale Asset Management opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 193,100 shares worth $927K. The stake represents 0.02% of the portfolio and ranks #552 among its holdings.

177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Martingale Asset Management held 193,100 shares of Arbutus Biopharma worth $927K as of Q2 2026.
  • Arbutus Biopharma was a new Martingale Asset Management position in Q2 2026.
  • Arbutus Biopharma made up 0.02% of Martingale Asset Management's portfolio in Q2 2026, its #552 holding.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.